<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MEDRXIV</journal-id>
<journal-title-group>
<journal-title>medRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">medRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/2021.02.26.21252199</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Genetic and Genomic Medicine</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Bidirectional Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of intermediate potential</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9979-2682</contrib-id>
<name><surname>Nakao</surname><given-names>Tetsushi</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5824-9595</contrib-id>
<name><surname>Bick</surname><given-names>Alexander G.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Taub</surname><given-names>Margaret A.</given-names></name>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4026-8944</contrib-id>
<name><surname>Zekavat</surname><given-names>Seyedeh M.</given-names></name>
<xref ref-type="aff" rid="a7">7</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1846-0411</contrib-id>
<name><surname>Uddin</surname><given-names>Md M.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Niroula</surname><given-names>Abhishek</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Carty</surname><given-names>Cara L.</given-names></name>
<xref ref-type="aff" rid="a8">8</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lane</surname><given-names>John</given-names></name>
<xref ref-type="aff" rid="a9">9</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8630-5021</contrib-id>
<name><surname>Honigberg</surname><given-names>Michael C.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a10">10</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7013-1899</contrib-id>
<name><surname>Weinstock</surname><given-names>Joshua S.</given-names></name>
<xref ref-type="aff" rid="a11">11</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4167-0540</contrib-id>
<name><surname>Pampana</surname><given-names>Akhil</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gibson</surname><given-names>Christopher J.</given-names></name>
<xref ref-type="aff" rid="a10">10</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Griffin</surname><given-names>Gabriel K.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a12">12</xref>
<xref ref-type="aff" rid="a13">13</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Clarke</surname><given-names>Shoa L.</given-names></name>
<xref ref-type="aff" rid="a14">14</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bhattacharya</surname><given-names>Romit</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a15">15</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Assimes</surname><given-names>Themistocles L.</given-names></name>
<xref ref-type="aff" rid="a14">14</xref>
<xref ref-type="aff" rid="a16">16</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9070-9886</contrib-id>
<name><surname>Emery</surname><given-names>Leslie S.</given-names></name>
<xref ref-type="aff" rid="a17">17</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3910-0776</contrib-id>
<name><surname>Stilp</surname><given-names>Adrienne M.</given-names></name>
<xref ref-type="aff" rid="a17">17</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9027-2100</contrib-id>
<name><surname>Wong</surname><given-names>Quenna</given-names></name>
<xref ref-type="aff" rid="a17">17</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Broome</surname><given-names>Jai</given-names></name>
<xref ref-type="aff" rid="a17">17</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6569-2501</contrib-id>
<name><surname>Laurie</surname><given-names>Cecelia A.</given-names></name>
<xref ref-type="aff" rid="a17">17</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Khan</surname><given-names>Alyna T.</given-names></name>
<xref ref-type="aff" rid="a17">17</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1942-5845</contrib-id>
<name><surname>Smith</surname><given-names>Albert V.</given-names></name>
<xref ref-type="aff" rid="a11">11</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Blackwell</surname><given-names>Thomas W.</given-names></name>
<xref ref-type="aff" rid="a11">11</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Yoneda</surname><given-names>Zachary T.</given-names></name>
<xref ref-type="aff" rid="a18">18</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Peralta</surname><given-names>Juan M.</given-names></name>
<xref ref-type="aff" rid="a19">19</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bowden</surname><given-names>Donald W.</given-names></name>
<xref ref-type="aff" rid="a20">20</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Irvin</surname><given-names>Marguerite R.</given-names></name>
<xref ref-type="aff" rid="a21">21</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Boorgula</surname><given-names>Meher</given-names></name>
<xref ref-type="aff" rid="a22">22</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhao</surname><given-names>Wei</given-names></name>
<xref ref-type="aff" rid="a23">23</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Yanek</surname><given-names>Lisa R.</given-names></name>
<xref ref-type="aff" rid="a24">24</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2749-1279</contrib-id>
<name><surname>Wiggins</surname><given-names>Kerri L.</given-names></name>
<xref ref-type="aff" rid="a25">25</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hixson</surname><given-names>James E.</given-names></name>
<xref ref-type="aff" rid="a26">26</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gu</surname><given-names>C. Charles</given-names></name>
<xref ref-type="aff" rid="a27">27</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Peloso</surname><given-names>Gina M.</given-names></name>
<xref ref-type="aff" rid="a28">28</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Roden</surname><given-names>Dan M.</given-names></name>
<xref ref-type="aff" rid="a29">29</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Reupena</surname><given-names>Muagututi&#x2019;a S.</given-names></name>
<xref ref-type="aff" rid="a30">30</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hwu</surname><given-names>Chii-Min</given-names></name>
<xref ref-type="aff" rid="a31">31</xref>
<xref ref-type="aff" rid="a32">32</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>DeMeo</surname><given-names>Dawn L.</given-names></name>
<xref ref-type="aff" rid="a33">33</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>North</surname><given-names>Kari E.</given-names></name>
<xref ref-type="aff" rid="a34">34</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kelly</surname><given-names>Shannon</given-names></name>
<xref ref-type="aff" rid="a35">35</xref>
<xref ref-type="aff" rid="a36">36</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Musani</surname><given-names>Solomon K.</given-names></name>
<xref ref-type="aff" rid="a37">37</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3409-1110</contrib-id>
<name><surname>Bis</surname><given-names>Joshua C.</given-names></name>
<xref ref-type="aff" rid="a38">38</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lloyd-Jones</surname><given-names>Donald M.</given-names></name>
<xref ref-type="aff" rid="a39">39</xref>
<xref ref-type="aff" rid="a40">40</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Johnsen</surname><given-names>Jill M.</given-names></name>
<xref ref-type="aff" rid="a41">41</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Preuss</surname><given-names>Michael</given-names></name>
<xref ref-type="aff" rid="a42">42</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tracy</surname><given-names>Russell P.</given-names></name>
<xref ref-type="aff" rid="a43">43</xref>
<xref ref-type="aff" rid="a61">61</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Peyser</surname><given-names>Patricia A.</given-names></name>
<xref ref-type="aff" rid="a23">23</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Qiao</surname><given-names>Dandi</given-names></name>
<xref ref-type="aff" rid="a33">33</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Desai</surname><given-names>Pinkal</given-names></name>
<xref ref-type="aff" rid="a44">44</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6898-155X</contrib-id>
<name><surname>Curran</surname><given-names>Joanne E.</given-names></name>
<xref ref-type="aff" rid="a19">19</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Freedman</surname><given-names>Barry I.</given-names></name>
<xref ref-type="aff" rid="a45">45</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tiwari</surname><given-names>Hemant K.</given-names></name>
<xref ref-type="aff" rid="a46">46</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chavan</surname><given-names>Sameer</given-names></name>
<xref ref-type="aff" rid="a22">22</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3575-5468</contrib-id>
<name><surname>Smith</surname><given-names>Jennifer A.</given-names></name>
<xref ref-type="aff" rid="a23">23</xref>
<xref ref-type="aff" rid="a47">47</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3483-353X</contrib-id>
<name><surname>Smith</surname><given-names>Nicholas L.</given-names></name>
<xref ref-type="aff" rid="a48">48</xref>
<xref ref-type="aff" rid="a49">49</xref>
<xref ref-type="aff" rid="a50">50</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kelly</surname><given-names>Tanika N.</given-names></name>
<xref ref-type="aff" rid="a51">51</xref>
<xref ref-type="aff" rid="a52">52</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hildalgo</surname><given-names>Bertha</given-names></name>
<xref ref-type="aff" rid="a46">46</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Cupples</surname><given-names>L. Adrienne</given-names></name>
<xref ref-type="aff" rid="a28">28</xref>
<xref ref-type="aff" rid="a53">53</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Weeks</surname><given-names>Daniel E.</given-names></name>
<xref ref-type="aff" rid="a54">54</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hawley</surname><given-names>Nicola L.</given-names></name>
<xref ref-type="aff" rid="a55">55</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Minster</surname><given-names>Ryan L.</given-names></name>
<xref ref-type="aff" rid="a56">56</xref>
</contrib>
<contrib contrib-type="author">
<collab>The Samoan Obesity, Lifestyle and Genetic Adaptations Study (OLaGA) Group</collab>
</contrib>
<contrib contrib-type="author">
<name><surname>Deka</surname><given-names>Ranjan</given-names></name>
<xref ref-type="aff" rid="a57">57</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Naseri</surname><given-names>Take T.</given-names></name>
<xref ref-type="aff" rid="a58">58</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>de las Fuentes</surname><given-names>Lisa</given-names></name>
<xref ref-type="aff" rid="a27">27</xref>
<xref ref-type="aff" rid="a59">59</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7892-193X</contrib-id>
<name><surname>Raffield</surname><given-names>Laura M.</given-names></name>
<xref ref-type="aff" rid="a60">60</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Morrison</surname><given-names>Alanna C.</given-names></name>
<xref ref-type="aff" rid="a26">26</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Vries</surname><given-names>Paul S.</given-names></name>
<xref ref-type="aff" rid="a26">26</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ballantyne</surname><given-names>Christie M.</given-names></name>
<xref ref-type="aff" rid="a62">62</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kenny</surname><given-names>Eimear E.</given-names></name>
<xref ref-type="aff" rid="a63">63</xref>
<xref ref-type="aff" rid="a64">64</xref>
<xref ref-type="aff" rid="a65">65</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Rich</surname><given-names>Stephen S.</given-names></name>
<xref ref-type="aff" rid="a66">66</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Whitsel</surname><given-names>Eric A.</given-names></name>
<xref ref-type="aff" rid="a34">34</xref>
<xref ref-type="aff" rid="a67">67</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4907-1657</contrib-id>
<name><surname>Cho</surname><given-names>Michael H.</given-names></name>
<xref ref-type="aff" rid="a68">68</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Shoemaker</surname><given-names>M. Benjamin</given-names></name>
<xref ref-type="aff" rid="a18">18</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Pace</surname><given-names>Betty S.</given-names></name>
<xref ref-type="aff" rid="a69">69</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6250-5723</contrib-id>
<name><surname>Blangero</surname><given-names>John</given-names></name>
<xref ref-type="aff" rid="a19">19</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Palmer</surname><given-names>Nicholette D.</given-names></name>
<xref ref-type="aff" rid="a20">20</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mitchell</surname><given-names>Braxton D.</given-names></name>
<xref ref-type="aff" rid="a70">70</xref>
<xref ref-type="aff" rid="a71">71</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Shuldiner</surname><given-names>Alan R.</given-names></name>
<xref ref-type="aff" rid="a72">72</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Barnes</surname><given-names>Kathleen C.</given-names></name>
<xref ref-type="aff" rid="a22">22</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6585-1610</contrib-id>
<name><surname>Redline</surname><given-names>Susan</given-names></name>
<xref ref-type="aff" rid="a10">10</xref>
<xref ref-type="aff" rid="a73">73</xref>
<xref ref-type="aff" rid="a74">74</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kardia</surname><given-names>Sharon L.R.</given-names></name>
<xref ref-type="aff" rid="a23">23</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Abecasis</surname><given-names>Gon&#x00E7;alo R.</given-names></name>
<xref ref-type="aff" rid="a11">11</xref>
<xref ref-type="aff" rid="a75">75</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Becker</surname><given-names>Lewis C.</given-names></name>
<xref ref-type="aff" rid="a24">24</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7100-512X</contrib-id>
<name><surname>Heckbert</surname><given-names>Susan R.</given-names></name>
<xref ref-type="aff" rid="a48">48</xref>
<xref ref-type="aff" rid="a49">49</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8286-9652</contrib-id>
<name><surname>He</surname><given-names>Jiang</given-names></name>
<xref ref-type="aff" rid="a51">51</xref>
<xref ref-type="aff" rid="a52">52</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Post</surname><given-names>Wendy</given-names></name>
<xref ref-type="aff" rid="a76">76</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Arnett</surname><given-names>Donna K.</given-names></name>
<xref ref-type="aff" rid="a77">77</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Vasan</surname><given-names>Ramachandran S.</given-names></name>
<xref ref-type="aff" rid="a28">28</xref>
<xref ref-type="aff" rid="a53">53</xref>
<xref ref-type="aff" rid="a78">78</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Darbar</surname><given-names>Dawood</given-names></name>
<xref ref-type="aff" rid="a79">79</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Weiss</surname><given-names>Scott T.</given-names></name>
<xref ref-type="aff" rid="a10">10</xref>
<xref ref-type="aff" rid="a33">33</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1233-6970</contrib-id>
<name><surname>McGarvey</surname><given-names>Stephen T.</given-names></name>
<xref ref-type="aff" rid="a80">80</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>de Andrade</surname><given-names>Mariza</given-names></name>
<xref ref-type="aff" rid="a81">81</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chen</surname><given-names>Yii-Der Ida</given-names></name>
<xref ref-type="aff" rid="a82">82</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kaplan</surname><given-names>Robert C.</given-names></name>
<xref ref-type="aff" rid="a83">83</xref>
<xref ref-type="aff" rid="a84">84</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Meyers</surname><given-names>Deborah A.</given-names></name>
<xref ref-type="aff" rid="a85">85</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Custer</surname><given-names>Brian S.</given-names></name>
<xref ref-type="aff" rid="a35">35</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Correa</surname><given-names>Adolfo</given-names></name>
<xref ref-type="aff" rid="a86">86</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Psaty</surname><given-names>Bruce M.</given-names></name>
<xref ref-type="aff" rid="a38">38</xref>
<xref ref-type="aff" rid="a48">48</xref>
<xref ref-type="aff" rid="a87">87</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0677-8158</contrib-id>
<name><surname>Fornage</surname><given-names>Myriam</given-names></name>
<xref ref-type="aff" rid="a26">26</xref>
<xref ref-type="aff" rid="a88">88</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Manson</surname><given-names>JoAnn E.</given-names></name>
<xref ref-type="aff" rid="a10">10</xref>
<xref ref-type="aff" rid="a89">89</xref>
<xref ref-type="aff" rid="a90">90</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Boerwinkle</surname><given-names>Eric</given-names></name>
<xref ref-type="aff" rid="a11">11</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Konkle</surname><given-names>Barbara A.</given-names></name>
<xref ref-type="aff" rid="a25">25</xref>
<xref ref-type="aff" rid="a91">91</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Loos</surname><given-names>Ruth J.F.</given-names></name>
<xref ref-type="aff" rid="a42">42</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Rotter</surname><given-names>Jerome I.</given-names></name>
<xref ref-type="aff" rid="a82">82</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Silverman</surname><given-names>Edwin K.</given-names></name>
<xref ref-type="aff" rid="a33">33</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kooperberg</surname><given-names>Charles</given-names></name>
<xref ref-type="aff" rid="a92">92</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jaiswal</surname><given-names>Siddhartha</given-names></name>
<xref ref-type="aff" rid="a93">93</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Libby</surname><given-names>Peter</given-names></name>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="aff" rid="a10">10</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2067-0533</contrib-id>
<name><surname>Ellinor</surname><given-names>Patrick T.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a94">94</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Pankratz</surname><given-names>Nathan</given-names></name>
<xref ref-type="aff" rid="a9">9</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-1669-2501</contrib-id>
<name><surname>Ebert</surname><given-names>Benjamin L.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a95">95</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Reiner</surname><given-names>Alexander P.</given-names></name>
<xref ref-type="aff" rid="a92">92</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mathias</surname><given-names>Rasika A.</given-names></name>
<xref ref-type="aff" rid="a24">24</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3144-3627</contrib-id>
<name><surname>Do</surname><given-names>Ron</given-names></name>
<xref ref-type="aff" rid="a42">42</xref>
<xref ref-type="aff" rid="a65">65</xref>
<xref ref-type="aff" rid="a96">96</xref>
</contrib>
<contrib contrib-type="author">
<collab>NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium</collab>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8402-7435</contrib-id>
<name><surname>Natarajan</surname><given-names>Pradeep</given-names></name>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a10">10</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Broad Institute of MIT and Harvard</institution>, Cambridge, MA, <country>USA</country></aff>
<aff id="a2"><label>2</label><institution>Cardiovascular Research Center, Massachusetts General Hospital</institution>, Boston, MA, <country>USA</country></aff>
<aff id="a3"><label>3</label><institution>Deparment of Medical Oncology, Dana-Farber Cancer Institute</institution>, Boston, MA, <country>USA</country></aff>
<aff id="a4"><label>4</label><institution>Division of Cardiovascular Medicine, Depatrment of Medicine, Brigham and Women&#x2019;s Hostpital</institution>, Boston, MA, <country>USA</country></aff>
<aff id="a5"><label>5</label><institution>Division of Genetic Medicine, Department of Medicine, Vanderbilt University</institution>, Nashville, TN, <country>USA</country></aff>
<aff id="a6"><label>6</label><institution>Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health</institution>, Baltimore, MD, <country>USA</country></aff>
<aff id="a7"><label>7</label><institution>Yale University School of Medicine</institution>, New Haven, CT, <country>USA</country></aff>
<aff id="a8"><label>8</label><institution>Initiative for Research and Education to Advance Community Health, Washington State University</institution>, Seattle, WA, <country>USA</country></aff>
<aff id="a9"><label>9</label><institution>Departmen of Laboratory Medicine and Pathology, University of Minnesota Medicall School</institution>, Minneapolis, MN, <country>USA</country></aff>
<aff id="a10"><label>10</label><institution>Department of Medicine, Harvard Medical School</institution>, Boston, MA, <country>USA</country></aff>
<aff id="a11"><label>11</label><institution>Center for Statistical Genetics, Department of Biosatistics, University of Michigan School of Public Health</institution>, Ann Arbor, MI, <country>USA</country></aff>
<aff id="a12"><label>12</label><institution>Departmentof Pathology, Harvard Medical School</institution>, Boston, MA, <country>USA</country></aff>
<aff id="a13"><label>13</label><institution>Department of Pathology, Brigham and Women&#x2019;s Hospital</institution>, Boston, MA, <country>USA</country></aff>
<aff id="a14"><label>14</label><institution>Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine</institution>, Stanford, CA, <country>USA</country></aff>
<aff id="a15"><label>15</label><institution>Division of Cardiology, Massachusettes General Hospital</institution>, Boston, MA, <country>USA</country></aff>
<aff id="a16"><label>16</label><institution>VA Palo Alto Health Care System</institution>, Palo Alto, CA, <country>USA</country></aff>
<aff id="a17"><label>17</label><institution>Department of Biostatistics, University of Washington</institution>, Seattle, WA, <country>USA</country></aff>
<aff id="a18"><label>18</label><institution>Division of Cardiology, Vanderbit University Medical Center</institution>, Nashville, TN, <country>USA</country></aff>
<aff id="a19"><label>19</label><institution>Department of Human Genetics and South Texas Diabetes and Obesity Institute, University of Texas Rio Grande Valley School of Medicine</institution>, Brownsville, TX, <country>USA</country></aff>
<aff id="a20"><label>20</label><institution>Department of Biochemistry, Wake Forest School of Medicine</institution>, Winston-Salem, NC, <country>USA</country></aff>
<aff id="a21"><label>21</label><institution>Department of Biostatistic, School of Public Health, University of Almbama</institution>, Birmingham, AL, <country>USA</country></aff>
<aff id="a22"><label>22</label><institution>Division of BioMedical Informatics &#x0026; Personalized Medicine &#x0026;the Colorado Center for Personlized Medicine, Schoolof Medicine, University of Colorado</institution>, Aurora, CO, <country>USA</country></aff>
<aff id="a23"><label>23</label><institution>Department of Epidemiology, School of Public Health, University of Michigan</institution>, Ann Arbor, MI, <country>USA</country></aff>
<aff id="a24"><label>24</label><institution>GeneSTAR Research Program, Department of Medicine, Johns Hopkins University School of Medicine</institution>, Baltimore, MD, <country>USA</country></aff>
<aff id="a25"><label>25</label><institution>Department of Medicine, University of Washington, Seattle</institution>, WA, <country>USA</country></aff>
<aff id="a26"><label>26</label><institution>Human Genetics Center, Department of Epidemiology, Human Genetics, and Environmental Science, School of Public Health, The University of Texas Health Science Center at Houston</institution>, Houston, TX, <country>USA</country></aff>
<aff id="a27"><label>27</label><institution>Division of Biostatistics, Washington University School of Medicine</institution>, St. Louis, MO, <country>USA</country></aff>
<aff id="a28"><label>28</label><institution>Department of Biostatistics, Boston University School of Public Health</institution>, Boston, MA, <country>USA</country></aff>
<aff id="a29"><label>29</label><institution>Department of Medicine, Pharmacology, and Biomedical Informatics, Vanderbilt University Medical Center</institution>, Nashville, TN, <country>USA</country></aff>
<aff id="a30"><label>30</label><institution>Ministry of Health, Government of Samoa</institution>, Apia, Samoa</aff>
<aff id="a31"><label>31</label><institution>Section of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital</institution>, Taipei, <country>Taiwan</country></aff>
<aff id="a32"><label>32</label><institution>School of Medicine, National Yang-Ming University</institution>, Taipei, <country>Taiwan</country></aff>
<aff id="a33"><label>33</label><institution>Channing Division of Network Medicine, Department of Medicine, Brigham and Women&#x2019;s Hospital</institution>, Boston, MA, <country>USA</country></aff>
<aff id="a34"><label>34</label><institution>Department of Epidemiology, Gilling School of Global Public Health, University of North Carolina</institution>, Chapel Hill, NC, <country>USA</country></aff>
<aff id="a35"><label>35</label><institution>Vitalant Research Institute</institution>, San Francisco, CA, <country>USA</country></aff>
<aff id="a36"><label>36</label><institution>UCSF, Benioff Children&#x2019;s Hospital Oakland</institution>, Oakland, CA, <country>USA</country></aff>
<aff id="a37"><label>37</label><institution>Jackson Heart Study, Department of Medicine, University of Mississippi Medical Center</institution>, Jackson, MS, <country>USA</country></aff>
<aff id="a38"><label>38</label><institution>Cardiovascular Health Research Unit, Department of Medicine, University of Washington</institution>, Seattle, WA, <country>USA</country></aff>
<aff id="a39"><label>39</label><institution>Division of Cardiology Department of Medicine, Northwestern University Feinberg School of Medicine</institution>, Chicago, IL, <country>USA</country></aff>
<aff id="a40"><label>40</label><institution>Department of Preventive Medicine, Northwestern University Feinberg School of Medicine</institution>, Chicago, IL, <country>USA</country></aff>
<aff id="a41"><label>41</label><institution>Bloodworks Northwest Research Institute</institution>, Seattle, WA, <country>USA</country></aff>
<aff id="a42"><label>42</label><institution>The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai</institution>, New York, NY, <country>USA</country></aff>
<aff id="a43"><label>43</label><institution>Department of Pathology and Laboratory Medicine, Larner College of Medicine, University of Vermont</institution>, Burlington, VT, <country>USA</country></aff>
<aff id="a44"><label>44</label><institution>Division of Hematology and Oncology, Weill Cornell Medical College</institution>, New York, NY, <country>USA</country></aff>
<aff id="a45"><label>45</label><institution>Internal Medicine&#x2013;Nephrology, Wake Forest School of Medicine</institution>, NC, <country>USA</country></aff>
<aff id="a46"><label>46</label><institution>Department of Epidemiology, School of Public Health, University of Alabama</institution>, Birmingham, AL, <country>USA</country></aff>
<aff id="a47"><label>47</label><institution>Survey Research Center, Institute for Social Research, University of Michigan</institution>, Ann Arbor, MI, <country>USA</country></aff>
<aff id="a48"><label>48</label><institution>Department of Epidemiology, University of Washington</institution>, Seattle, WA, <country>USA</country></aff>
<aff id="a49"><label>49</label><institution>Kaiser Permanente Washington Health Research Institute</institution>, Seattle, WA, <country>USA</country></aff>
<aff id="a50"><label>50</label><institution>Seattle Epidemiologic Research and Information Center, Department of Veterans Affair Office of Research and Development</institution>, Seattle, WA, <country>USA</country></aff>
<aff id="a51"><label>51</label><institution>Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine</institution>, New Orleans, LA, <country>USA</country></aff>
<aff id="a52"><label>52</label><institution>Tulane University Translational Science Institute</institution>, New Orleans, LA, <country>USA</country></aff>
<aff id="a53"><label>53</label><institution>National Heart Lung and Blood Institute&#x2019;s, Boston University&#x2019;s Framingham Heart Study</institution>, Framingham, MA, <country>USA</country></aff>
<aff id="a54"><label>54</label><institution>Department of Human Genetics and Biostatistic, University of Pittsburgh</institution>, PA, <country>USA</country></aff>
<aff id="a55"><label>55</label><institution>Department of Chronic Disease Epidemiology, Yale University</institution>, CT, <country>USA</country></aff>
<aff id="a56"><label>56</label><institution>Department of Human Genetics, University of Pittsburgh</institution>, PA, <country>USA</country></aff>
<aff id="a57"><label>57</label><institution>Department of Environmental Health, University of Cincinnati</institution>, OH, <country>USA</country></aff>
<aff id="a58"><label>58</label><institution>Department of Health, American Samoa Government, Pago Pago, American Samoa</institution>, <country>USA</country></aff>
<aff id="a59"><label>59</label><institution>Cardiovascular Division, Department of Medicine, Washington University School of Medicine</institution>, St. Louis, MO, <country>USA</country></aff>
<aff id="a60"><label>60</label><institution>Department of Genetics, University of North Carolina, Chapel Hill</institution>, NC, <country>USA</country></aff>
<aff id="a61"><label>61</label><institution>Department of Pathology and Biochemistry, University of Vermont College of Medicine</institution>, Burlington, VT, <country>USA</country></aff>
<aff id="a62"><label>62</label><institution>Department of Medicine, Baylor College of Medicine</institution>, Houston, TX, <country>USA</country></aff>
<aff id="a63"><label>63</label><institution>Institute for Genomic Health, Icahn School of Medicine a Mount Sinai</institution>, New York, NY, <country>USA</country></aff>
<aff id="a64"><label>64</label><institution>Department of Medicine, Icahn School of Medicine a Mount Sinai</institution>, New York, NY, <country>USA</country></aff>
<aff id="a65"><label>65</label><institution>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai</institution>, New York, NY, <country>USA</country></aff>
<aff id="a66"><label>66</label><institution>Center for Public Health Genomics, University of Virginia</institution>, Charlottesville, VA, <country>USA</country></aff>
<aff id="a67"><label>67</label><institution>Department of Medicine, School of Medicine, University of North Carolina</institution>, Chapel Hill, NC, <country>USA</country></aff>
<aff id="a68"><label>68</label><institution>Channing Division of Network Medicine and Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women&#x2019;s Hospital</institution>, Boston, MA, <country>USA</country></aff>
<aff id="a69"><label>69</label><institution>Division of Hematology/Oncology, Department of Pediatrics, Augusta University</institution>, Augusta, GA, <country>USA</country></aff>
<aff id="a70"><label>70</label><institution>Department of Medicine, University of Maryland School of Medicine</institution>, Balimore, MD, <country>USA</country></aff>
<aff id="a71"><label>71</label><institution>Geriatrics Research and Education Clinical Center, Baltimore Veterans Administration Medical Center</institution>, Baltimore, MD, <country>USA</country></aff>
<aff id="a72"><label>72</label><institution>Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine</institution>, Baltimore, MD, <country>USA</country></aff>
<aff id="a73"><label>73</label><institution>Division of Sleep and Circadian Disorders, Department of Medicine, Brigha and Women&#x2019;s Hospital</institution>, Boston, MA, <country>USA</country></aff>
<aff id="a74"><label>74</label><institution>Department of Medicine, Beth Israel Deacone Medical Center</institution>, Boston, MA, <country>USA</country></aff>
<aff id="a75"><label>75</label><institution>Regeneron Pharmaceuticals, Tarrytown</institution>, NY, <country>USA</country></aff>
<aff id="a76"><label>76</label><institution>Department of Medicine, Division of Cardiology, Johns Hopkins University</institution>, Baltimore, MD, <country>USA</country></aff>
<aff id="a77"><label>77</label><institution>Dean&#x2019;s Office, College of Public Health, University of Kentucky</institution>, Lexington, KY, <country>USA</country></aff>
<aff id="a78"><label>78</label><institution>Departments of Cardiology and Preventive Medicine, Department of Medicine, Boston University School of Medicine</institution>, Boston, MA, <country>USA</country></aff>
<aff id="a79"><label>79</label><institution>Division of Cardiology, University of Illinois a Chicago</institution>, Chicago, IL, <country>USA</country></aff>
<aff id="a80"><label>80</label><institution>Department of Epidemiology and International Health Institute, Brown University School of Public Health</institution>, Providence, RI, <country>USA</country></aff>
<aff id="a81"><label>81</label><institution>Mayo Clinic, Department of Health Sciences Research</institution>, Rochester, MN, <country>USA</country></aff>
<aff id="a82"><label>82</label><institution>The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</institution>, Torrance, CA, <country>USA</country></aff>
<aff id="a83"><label>83</label><institution>Department of Epidemiology and Population Health, Alber Einstein College of Medicine</institution>, Bronx, NY, <country>USA</country></aff>
<aff id="a84"><label>84</label><institution>Fred Hutchinson Cancer Research Center, Division of Public Health Sciences</institution>, Seattle, WA, <country>USA</country></aff>
<aff id="a85"><label>85</label><institution>Division of Genetics, Genomics and Precision Medicine, University of Arizona</institution>, Tucson, AZ, <country>USA</country></aff>
<aff id="a86"><label>86</label><institution>Department of Medicine and Population Health Science, University of Mississippi Medical Center</institution>, Jackson, MS, <country>USA</country></aff>
<aff id="a87"><label>87</label><institution>Department of Health Services University of Washington</institution>, Seattle, WA, <country>USA</country></aff>
<aff id="a88"><label>88</label><institution>Brown Foundation Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houson</institution>, Houson, TX, <country>USA</country></aff>
<aff id="a89"><label>89</label><institution>Department of Medicine, Brighamand Women&#x2019;s Hospital</institution>, Boston, MA, <country>USA</country></aff>
<aff id="a90"><label>90</label><institution>Department of Epidemiology, Harvard T.H. Chan School of Public Health</institution>, Boston, MA, <country>USA</country></aff>
<aff id="a91"><label>91</label><institution>Bloodwork Northwest</institution>, Seattle, WA, <country>USA</country></aff>
<aff id="a92"><label>92</label><institution>Fred Hutchinson on Cancer Research Center</institution>, Seattle, WA, <country>USA</country></aff>
<aff id="a93"><label>93</label><institution>Department of Pathology, Stanford University</institution>, Stanford, CA, <country>USA</country></aff>
<aff id="a94"><label>94</label><institution>Cardiac Arrhythmia Service and Cardiovascular Research Center, Massachuttes General Hospital</institution>, Boston, MA, <country>USA</country></aff>
<aff id="a95"><label>95</label><institution>Howard Hughes Medical Institute</institution>, Boston, MA, <country>USA</country></aff>
<aff id="a96"><label>96</label><institution>Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai</institution>, New York, NY, <country>USA</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>&#x002A;</label>Please address correspondence to: Pradeep Natarajan, MD MMSc, 185 Cambridge Street, CPZN 3.184, Boston, MA 02114, Office: 617-726-1843, Email: <email>pnatarajan@mgh.harvard.edu</email>, Twitter: @pnatarajanmd</corresp>
</author-notes>
<pub-date pub-type="epub">
<year>2021</year>
</pub-date>
<elocation-id>2021.02.26.21252199</elocation-id>
<history>
<date date-type="received">
<day>26</day>
<month>2</month>
<year>2021</year>
</date>
<date date-type="rev-recd">
<day>26</day>
<month>2</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>01</day>
<month>3</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2021, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2021</copyright-year>
<license><license-p>The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.</license-p></license>
</permissions>
<self-uri xlink:href="21252199.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title>
<p>Human genetic studies support an inverse causal relationship between leukocyte telomere length (LTL) and coronary artery disease (CAD), but directionally mixed effects for LTL and diverse malignancies. Clonal hematopoiesis of indeterminate potential (CHIP), characterized by expansion of hematopoietic cells bearing leukemogenic mutations, predisposes both hematologic malignancy and CAD. <italic>TERT</italic> (which encodes telomerase reverse transcriptase) is the most significantly associated germline locus for CHIP in genome-wide association studies. Here, we investigated the relationship between CHIP, LTL, and CAD in Trans-Omics for Precision Medicine (TOPMed) program (N=63,302) and UK Biobank (N=48,658). Bidirectional Mendelian randomization studies were consistent with LTL lengthening increasing propensity to develop CHIP, but CHIP then in turn hastening LTL shortening. We also demonstrated evidence of modest mediation between CHIP and CAD by LTL. Our data promote an understanding of potential causal relationships across CHIP and LTL toward prevention of CAD.</p>
</abstract>
<counts>
<page-count count="27"/>
</counts>
</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></notes>
<notes notes-type="financial-disclosure">
<title>Funding Statement</title><p>The whole-genome sequence for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung, and Blood Institute (NHLBI). Core support including centralized genomic read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Core support including phenotype harmonization, data management, sample-identity QC, and general program coordination was provided by the TOPMed Data Coordinating Center (R01HL-120393; U01HL-120393; contract HHSN268201800001I). Phenotype harmonization for coronary artery disease in TOPMed was supported by National Heart, Lung and Blood Institute (NHLBI) grant number R01HL146860.</p></notes>
<notes notes-type="disclosures">
<title>Author Declarations</title><p>I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.</p><p>Yes</p><p>The details of the IRB/oversight body that provided approval or exemption for the research described are given below:</p><p>All WHI participants provided informed consent and the study was approved by the Institutional Review Board of the Fred Hutchinson Cancer Research Center. All COPDGene participants provided written informed consent, and the study was approved by the Institutional Review Boards of the participating clinical centers. All MESA participants provided written informed consent, and the study was approved by the Institutional Review Boards at The Lundquist Institute (formerly Los Angeles BioMedical Research Institute) at Harbor-UCLA Medical Center, University of Washington, Wake Forest School of Medicine, Northwestern University, University of Minnesota, Columbia University, and Johns Hopkins University. All BioMe subjects provided informed consent and the study was approved by the Institutional Review Board of Mount Sinai School of Medicine. All MLOF participants, and for children, their parents, gave written informed consent, which received human subjects Institutional Review Board approval at each hemophilia treatment center local clinical site. All ARIC participants provided written informed consent, and the study was approved by the Institutional Review Boards at the field centers and Collaborative Studies Coordinating Center at the University of North Carolina at Chapel Hill. All CARDIA participants provided informed consent, and the study was approved by the Institutional Review Boards of the University of Alabama at Birmingham and the University of Texas Health Science Center at Houston. All CHS participants provided informed consent, and the study was approved by the Institutional Review Board of University Washington. All JHS participants provided informed consent, and the study was approved by the Institutional Review Boards of the University of Mississippi Medical Center, Jackson State University, and Tougaloo College. All REDS-III Brazil participants provided written informed consent under a protocol reviewed by institutional review boards at the Vitalant Research Institute and Medical School of the University of Sao Paulo as well as the NHLBI REDS-III Observational Study Monitoring Board. For SARP, informed consent was obtained from the legal guardians of each child and verbal and written consent was obtained from participating children, and the study SARF was approved by the Institutional Review Board of each clinical center. All HCHS/SOL participants provided informed consent, and the study was approved by the Institutional Review Board of local field centers, coordinating centers, and laboratories. All ECLIPSE participants provided written informed consent, and the study was approved by the Institutional Review Boards of the participating clinical centers. All THRV participants provided informed consent and the study was approved by the Institutional Review Board of Washington University in St. Louis. All Mayo-VTE participants provided informed consent and the study was approved by the Institutional Review Board of the Mayo Clinic. All Samoan study participants provided written informed consent, and the study was approved by the Institutional Review Board at Brown University, and the Health Research Committee of the Samoa Ministry of Health. All subjects in the Genetics of Asthma in Costa Rica Study (GACR) provided informed consent and the study was approved by the Institutional Review Boards of the Hospital Des Ninos in San Juan Costa Rica and Brigham and Womens Hospital Boston MA. All VU-AF subjects provided informed consent and the study was approved by the Institutional Review Board (IRB) of Vanderbilt University. All FHS participants provided informed consent and the study was approved by the Institutional Review Board of Boston University. All HyperGEN participants provided informed consent, and the study was approved by the Institutional Review Board of the University of Kentucky.
All GenSalt participants provided informed consent and the study was approved by the Institutional Review Board of all participating institutes in the US and China. All HVH participants provided written informed consent and study approval was granted by the human subjects committee at Group Health. All GeneSTAR participants provided written informed consent and the study was approved by the Johns Hopkins Medicine Institutional Review Board. All GENOA participants provided informed consent and the study protocol was approved by the Human Studies Review Boards of the University of Mississippi, the Mayo Clinic, and the University of Texas. All subjects in the CFS provided informed consent and the study was approved by the Institutional Review Board of Case Western Reserve University and Mass General Brigham (formerly Partners HealthCare). All BAGS participants gave verbal and written consent as approved by the Johns Hopkins Institutional Review Board and the Barbados Ministry of Health. All Amish participant provided informed consent and the study protocols were approved by the institutional review board at the University of Maryland Baltimore. All GOLDN participants provided informed consent, and the study was approved by the Institutional Review Board of the University of Kentucky. All DHS participants provided written informed consent, and study protocols were approved by the institutional review board at Wake Forest School of Medicine. All SAFS participants provided informed consent, and the study was approved by Institutional Review Board at the University of Texas Rio Grande Valley. All PharmHU participants provided written informed consent and the study was approved by the Baylor College of Medicine IRB. All Boston Early-Onset COPD Study participants provided written informed consent, and the study was approved by the Institutional Review Board at Brigham and Womens Hospital. All VAFAR participants provided informed consent and the study was approved by the Institutional Review Board of Vanderbilt University. All participants in the UK Biobank study provided written informed consent and the ethics approval for the UK Biobank study was obtained as described before. UK Biobank Resource was used under application number 7089. Secondary use of the UK Biobank data was approved by the Massachusetts General Hospital institutional review board (protocol 2013P001840).</p><p>All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.</p><p>Yes</p><p>I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).</p><p>Yes</p><p>I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.</p><p>Yes</p></notes>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Telomeres consist of repetitive DNA sequences with associated protective proteins,<sup><xref ref-type="bibr" rid="c1">1</xref></sup> that stabilize chromosomes by several mechanisms.<sup><xref ref-type="bibr" rid="c2">2</xref></sup> Shortening of telomeres during successive mitoses aims to protect the remaining chromosomal DNA. Reverse transcription by the telomerase complex mitigates telomere attrition in cells requiring frequent division such as hematopoietic stem cells.<sup><xref ref-type="bibr" rid="c3">3</xref>-<xref ref-type="bibr" rid="c5">5</xref></sup> However, with aging, telomeres continue to shorten and protective mechanisms are less efficient leading to accumulating senescent cells with shortened telomeres providing a fertile substrate for genomic instability.<sup><xref ref-type="bibr" rid="c6">6</xref></sup> Senescent cells also acquire a proinflammatory senescence-associated secretory phenotype (SASP), which promotes aging-related cardiovascular disease.<sup><xref ref-type="bibr" rid="c7">7</xref></sup></p>
<p>While Mendelian randomization (MR) studies consistently support an inverse causal relationship between leukocyte telomere length (LTL) and coronary artery disease (CAD), the relationship between LTL and cancer is more complex.<sup><xref ref-type="bibr" rid="c8">8</xref>-<xref ref-type="bibr" rid="c10">10</xref></sup> <italic>In vitro</italic> studies indicate that short telomeres promote genomic instability, thereby leading to malignancies,<sup><xref ref-type="bibr" rid="c2">2</xref>,<xref ref-type="bibr" rid="c11">11</xref></sup> and most tumor cells have shortened telomeres.<sup><xref ref-type="bibr" rid="c12">12</xref>-<xref ref-type="bibr" rid="c15">15</xref></sup> Mendelian disorders characterized by severe telomere shortenings, such as aplastic anemia and dyskeratosis congenita, are characterized by premature aging, organ damage, and high rates of malignant blood disorders.<sup><xref ref-type="bibr" rid="c16">16</xref>,<xref ref-type="bibr" rid="c17">17</xref></sup> However, MR studies indicate that longer LTL may be causally associated with an increased incidence of various malignancies, such as lung adenocarcinoma, glioma, melanoma, or leukemia.<sup><xref ref-type="bibr" rid="c8">8</xref>-<xref ref-type="bibr" rid="c10">10</xref>,<xref ref-type="bibr" rid="c18">18</xref>-<xref ref-type="bibr" rid="c21">21</xref></sup></p>
<p>Age-related clonal hematopoiesis of indeterminate potential (CHIP), characterized by clonally expanded hematopoietic cells bearing leukemogenic mutations (most commonly in <italic>DNMT3A, TET2, ASXL1</italic>, and <italic>JAK2</italic>) without clinical hematologic disorders, represents a pre-malignant condition. CHIP strongly predicts future risk for myeloid malignancy and human and murine data indicate that CHIP is a causal risk factor for CAD as well.<sup><xref ref-type="bibr" rid="c22">22</xref>-<xref ref-type="bibr" rid="c27">27</xref></sup> In cross-sectional analyses, the presence of CHIP correlates with shorter LTL adjusting for age.<sup><xref ref-type="bibr" rid="c28">28</xref></sup> However similar to aforementioned cancer studies, in genome-wide association analyses of CHIP, the most significant risk allele resides in the <italic>TERT</italic> locus<sup><xref ref-type="bibr" rid="c29">29</xref></sup> (encoding telomerase reverse transcriptase) and is associated with lengthened LTL.<sup><xref ref-type="bibr" rid="c30">30</xref></sup> Whether and how CHIP and LTL are causally related is unknown, and whether this relationship influences CHIP-associated risk for CAD is unknown.</p>
<p>Here, we investigated the relationships between LTL, CHIP, and CAD to address these questions using LTL estimated from whole exome sequencing (WES) data in the UK Biobank (N &#x003D; 48,658) and from whole genome sequencing (WGS) data in the NHLBI TOPMed program (N &#x003D; 63,302).<sup><xref ref-type="bibr" rid="c30">30</xref>,<xref ref-type="bibr" rid="c31">31</xref></sup></p>
<p>After estimating the associations across LTL, CHIP, and CAD, we assessed these associations for evidence supporting bidirectional causality using MR. Finally, we estimated the mediation effect of LTL for the CHIP-associated CAD risk.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Baseline characteristics</title>
<p>CHIP was detected, and LTL was estimated with blood DNA-derived WGS from the U.S. National Heart, Lung, and Blood Institute (NHLBI) Trans-Omics for Precision Medicine (TOPMed) program<sup><xref ref-type="bibr" rid="c32">32</xref></sup> and WES from the UK Biobank.<sup><xref ref-type="bibr" rid="c33">33</xref></sup> In TOPMed, CHIP calls and LTL estimates were obtained from whole genome sequence analyses previously published.<sup><xref ref-type="bibr" rid="c29">29</xref>,<xref ref-type="bibr" rid="c30">30</xref></sup> In TOPMed, after excluding kinship through second-degree relatives, 63,302 individuals had both indices measured of whom 36,507 (57.7 %) were female. The mean age was 54.3 years old (standard deviation (SD) 18.0) at the time of blood draw, and 29,171 (64.6%) were of European ancestry (<xref rid="fig1" ref-type="fig">Fig. 1</xref>, Supplementary Fig. 1, Supplementary Table 1). CHIP calls from the first WES samples released from UK Biobank were obtained<sup><xref ref-type="bibr" rid="c27">27</xref>,<xref ref-type="bibr" rid="c33">33</xref></sup> with some modifications (see Methods), yielding 48,658 individuals after excluding related individuals (second-degree) and discordance between genetic sex and self-reported sex. Among the UK Biobank participants included, 26,515 (54.5 %) were female. The mean age was 56.5 years old (SD 8.0), and 43,227 (93.9%) were of European ancestry. In total, 3,284 (TOPMed: 5.1 %) and 2,273 (UK Biobank: 4.6 %) individuals had evidence of at least one CHIP-related mutation. Of these, 2,862 (TOPMed: 4.5 %) and 1,044 (UK Biobank: 2.1 %) individuals had variant allele frequency greater than 0.10, a threshold previously associated with increased CAD incidence<sup><xref ref-type="bibr" rid="c24">24</xref>,<xref ref-type="bibr" rid="c25">25</xref>,<xref ref-type="bibr" rid="c27">27</xref></sup> (Supplementary Table 1).</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Fig. 1:</label>
<caption><title>Analytical procedure in this study.</title>
<p>TOPMed (N=63,302) and UK Biobank (N=48,658) are used as the study cohorts. CHIP associated mutations are detected by Mutect2. Telomere length was estimated by TelSeq. Observational study and causal inference by bidirectional Mendelian randomization were performed between LTL and CHIP. CHIP was associated with shorter LTL. Germline genetic factors that increase CHIP development were associated with shorter LTL, whereas germline genetic factors that increase LTL were associated with developing CHIP. Mediation effect of LTL on CHIP related CAD risk increment was detected by causal mediation analysis. CHIP: clonal hematopoiesis of indeterminate potential, LTL: leukocyte telomere length, TOPMed: Trans-Omics for Precision Medicine, UKBB: UK Biobank.</p></caption>
<graphic xlink:href="21252199v1_fig1.tif"/>
</fig>
</sec>
<sec id="s2b">
<title>Telomere length estimation using WES in UK biobank</title>
<p>The TelSeq algorithm was applied to the 49,739 CRAM files of WES in the UK Biobank to estimate LTL. The same algorithm was used to estimate LTL from WGS data in TOPMed.<sup><xref ref-type="bibr" rid="c30">30</xref></sup> Consistent with restricted sequencing inherent to WES, the estimated absolute LTL (mean &#x00B1; SD (kb): 0.07 &#x00B1; 0.08) from WES in UK Biobank was much shorter than that estimated from WGS in TOPMed (mean &#x00B1; SD (kb): 3.27 &#x00B1; 1.01) or from conventional LTL measured by Southern blot (mean &#x00B1; SD (kb): 6.87 &#x00B1; 0.62) measured in a subset of the Women&#x2019;s Health Initiative (WHI) (N &#x003D; 686) (Supplementary Fig. 2a,b). LTL estimation was batch-corrected with the first nine principal components (PCs) generated by NGS-PCA (<ext-link ext-link-type="uri" xlink:href="https://github.com/PankratzLab/NGS-PCA">https://github.com/PankratzLab/NGS-PCA</ext-link>) which uses calculated from read coverage information that is standardized to assess the relative value (Supplementary Fig. 2c). Despite much shorter absolute estimates, the batch-corrected LTL normalized distribution much more closely approximated the expectation and so we focus on LTL SD unit hereafter. Variants previously associated with LTL were associated with LTL in UK Biobank similarly to prior qPCR-based telomere estimation (T/S ratio),<sup><xref ref-type="bibr" rid="c10">10</xref></sup> but with relative effect deflation (R<sup>2</sup> &#x003D; 0.69, <italic>P</italic> &#x003D; 3.02&#x00D7;10<sup>&#x2212;6</sup>) (Supplementary Fig. 3). Age was correlated with LTL in both TOPMed WGS (&#x03B2; &#x003D; -0.023, <italic>P</italic> &#x003C; 2&#x00D7;10<sup>&#x2212;16</sup>) and UK Biobank WES (&#x03B2; &#x003D; -0.0098, <italic>P</italic> &#x003C; 2&#x00D7;10<sup>&#x2212;16</sup>) after adjustment with sex, ever smoking, first 11 genetic PCs (Supplementary Fig. 2d).</p>
</sec>
<sec id="s2c">
<title>Shorter LTL is associated with increased CHIP prevalence and increased CAD incidence</title>
<p>We performed association studies between LTL, CHIP, and CAD separately in TOPMed and UK Biobank, followed by meta-analyses. Consistent with prior reports,<sup><xref ref-type="bibr" rid="c4">4</xref></sup> CHIP with variant allele frequency (VAF) &#x003E; 0.10 was associated with shorter LTL in meta-analysis results after adjustment for age, sex, ever smoking, body mass index (BMI), study, sequencing center, and first 11 genetic PCs (&#x03B2; &#x003D; -0.13; 95% CI -0.16:-0.096; P(heterogeneity)=0.02) (<xref rid="fig2" ref-type="fig">Fig. 2a</xref>, Supplementary Fig. 4a). Here, VAF was defined as the largest clone if multiple CHIP clones were detected in the same individual. CHIP with VAF &#x003C; 0.10 was associated with shorter LTL in TOPMed (WGS) but not in UK Biobank (WES), likely due to reduced sensitivity of smaller CHIP clones and improved LTL estimation with WGS relative to WES (Supplementary Fig. 4b).</p>
<fig id="fig2" position="float" fig-type="figure">
<label>Fig. 2:</label>
<caption><title>CHIP prevalence and VAF are associated with shorter LTL.</title>
<p>The associations of CHIP with LTL were assessed by linear regression model both in TOPMed and UK Biobank, then meta-analyzed by fixed effect model. Both models were adjusted with age, sex, ever smoking, body mass index, first 11 genetic principal components, study within TOPMed and sequencing center (study and sequencing center are only applicable to TOPMed). The prevalence of CHIP with greater than 10% VAF associations were evaluated for overall and each mutated gene (<bold>a</bold>) and for each number of mutated genes in the same individuals (<bold>b</bold>). <bold>c</bold> The correlation between LTL and VAF among the population with CHIP from both TOPMed and UK Biobank pooled analysis is displayed. A subset in TOPMed with age 40 to 70 was included in the analysis to align with the age distribution in UK Biobank. Red dotted line represents the average LTL in the population without CHIP. &#x002A;&#x002A; <italic>P</italic> &#x003C; 0.01, &#x002A;&#x002A;&#x002A; <italic>P</italic> &#x003C; 0.001, after Bonferroni&#x2019;s correction if applicable. CHIP: clonal hematopoiesis of indeterminate potential, DDR: DNA damage repair, LTL: leukocyte telomere length, TOPMed: Trans-Omics for Precision Medicine, VAF: variant allele frequency.</p></caption>
<graphic xlink:href="21252199v1_fig2.tif"/>
</fig>
<p>Prior cell-based studies have shown that <italic>DNMT3A</italic> loss of function increases telomere length,<sup><xref ref-type="bibr" rid="c34">34</xref></sup> <italic>TET2</italic> loss of function decreases telomere length;<sup><xref ref-type="bibr" rid="c35">35</xref>,<xref ref-type="bibr" rid="c36">36</xref></sup> and <italic>p53</italic> (TP53) protects telomeres from DNA damage.<sup><xref ref-type="bibr" rid="c37">37</xref></sup> Thus, we estimated the effect size of each mutated gene on LTL (<xref rid="fig2" ref-type="fig">Fig. 2a</xref>, Supplementary Fig. 5, Supplementary Table 2). <italic>DNMT3A</italic> did not show a significant association with LTL, whereas <italic>TET2, ASXL1, PPM1D, JAK2</italic>, and <italic>TP53</italic> were significantly associated with shorter LTL. Multiple CHIP mutations in the same individuals had an additive effect on shorter LTL (<xref rid="fig2" ref-type="fig">Fig. 2b</xref>, Supplementary Fig. 6a). Each additional CHIP-related mutation yielded an effect size of -0.11 when meta-analyzed across both cohorts (95% CI -0.14:-0.086; <italic>P</italic> &#x003D; 6. 83&#x00D7;10<sup>&#x2212;14</sup>) (Supplementary Fig. 6b).</p>
<p>Among those with CHIP, increasing VAF correlated strongly with shorter LTL after adjustment in both cohorts (&#x03B2; &#x003D; -1.12 / 1% of VAF; 95% CI -1.40:-0.84; P(heterogeneity)=0.14) (<xref rid="fig2" ref-type="fig">Fig. 2c</xref>, Supplementary Fig. 7).</p>
<p>We next assessed the association of LTL with CAD using subsets of the cohorts with information on incident CAD in TOPMed (N &#x003D; 27,937) and in UK Biobank (N &#x003D; 48,658). Individuals who experienced CAD prior to the blood draw used to determine CHIP status were excluded from TOPMed (N &#x003D; 416) and UK Biobank (N &#x003D; 1,357) analyses and follow up duration was calculated starting the time at the blood draw. Incident CAD was defined both in TOPMed and UK Biobank by ischemic heart disease, including myocardial infarction, and coronary revascularization (Supplementary Table 3).</p>
<p>We used Cox proportional hazard models to evaluate the association between LTL and CAD including multivariable adjustment with covariates age, sex, ever smoking, BMI, hypercholesterolemia, the first 11 genetic PCs, study within TOPMed, and sequencing center (study and sequencing center were only applicable to TOPMed). Missing covariates excluded 8,324 TOPMed (8,200 COPDGene participants without blood lipids, and 124 other individuals across TOPMed missing covariates) and 1,224 UK Biobank individuals from the analysis (Supplementary Fig. 1). Of the remaining 19,176 TOPMed and 46,077 UK Biobank individuals, 3,283 TOPMed (17.1%) and 1,379 UK Biobank (3.0%) participants developed CAD during the follow-up duration (mean (SD) duration 12.0 (5.8) years in TOPMed and 10.0 (1.5) years in UK Biobank) (The number of individuals included in the final analysis in each TOPMed cohort was shown in Supplementary Table 4). Shorter LTL was associated with increased CAD risk (Hazard Ratio &#x003D; 1.07; 95% CI 1.04:1.10; <italic>P</italic> (heterogeneity) &#x003D; 0.71) (Supplementary Fig. 8) as previously reported.<sup><xref ref-type="bibr" rid="c38">38</xref>-<xref ref-type="bibr" rid="c40">40</xref></sup></p>
</sec>
<sec id="s2d">
<title>Mendelian randomization studies indicate that CHIP causes shortened telomeres</title>
<p>We performed one-sample MR for CHIP on LTL with the TOPMed cohort. Instrumental variables (IVs) were utilized from a previously reported GWAS of CHIP.<sup><xref ref-type="bibr" rid="c29">29</xref></sup> To avoid the possible bias from reverse causality, we filtered discovered IVs using the Steiger test that identified the <italic>TERT</italic> locus as having a significantly higher correlation with LTL than CHIP (<italic>P</italic> &#x003D; 0.0105); hence, SNPs at <italic>KPNA4/TRIM59</italic> and <italic>TET2</italic> loci were valid IVs (Supplementary Table 5). The significance of each variant supported the robust association with exposure, the first assumption of Mendelian randomization (Supplementary Table 5). The MR analysis with 2 IVs was consistent with an inverse causal effect of CHIP on LTL (Estimate &#x003D; -0.81; 95% CI -1.40:-0.23; <italic>P</italic> &#x003D; 0.0063) (<xref rid="fig3" ref-type="fig">Fig. 3</xref>). No statistical evidence of endogeneity for IVs used was shown by the Sargan test (<italic>P</italic> &#x003D; 0.306). Single IV analysis demonstrated consistent effect sizes across 2 IVs (Supplementary Fig. 9).</p>
<fig id="fig3" position="float" fig-type="figure">
<label>Fig. 3:</label>
<caption><title>Bidirectional Mendelian randomization studies showed the negative causal effect of CHIP on LTL and the positive causal effect of LTL on CHIP.</title>
<p>Bidirectional one-sample MR was performed to assess the causal effect of both CHIP on LTL and LTL on CHIP. TOPMed was used for IV discovery for CHIP on LTL, Li et al <italic>AJHG</italic> 2020 for LTL on CHIP. IVs were clumped if &#x003C; 10 Mb apart and in linkage disequilibrium (R<sup>2</sup> &#x003E; 0.001 calculated in European ancestry from 1000 Genome project). IVs were further assessed by Steiger test to mitigate the effect of reverse causation resulting in 2 and 16 IVs, respectively. TOPMed was used as the test cohort for both CHIP on LTL and LTL on CHIP. Used IVs and cohorts for each analysis are summarized in Supplementary Tables 5 and 7. CHIP: Clonal hematopoiesis of intermediate potential, CI: confidence interval, IV: Instrumental variable, LTL: Leukocyte telomere length, MR: Mendelian randomization, TOPMed: Trans-Omics for Precision Medicine, UKBB: UK Biobank.</p></caption>
<graphic xlink:href="21252199v1_fig3.tif"/>
</fig>
<p>We next performed a two-sample MR study. The subset of European ancestry participants from TOPMed was used as the CHIP exposure cohort and publicly available summary statistics for LTL from the ENGAGE (European Network for Genetic and Genomic Epidemiology, N &#x003D; 37,684)<sup><xref ref-type="bibr" rid="c41">41</xref></sup> consortium were used for the outcome. The low heritability for CHIP, limitation to European ancestry samples, and removal of the one significant (<italic>P</italic> &#x003C; 5&#x00D7;10<sup>&#x2212;8</sup>) locus (<italic>TERT</italic> locus) in a European-only CHIP GWAS<sup><xref ref-type="bibr" rid="c29">29</xref></sup> due to Steiger filtering (<italic>P</italic> &#x003D; 0.011), to minimize bias from potential reverse causality, limited the power for conventional two-sample MR analyses. Therefore, we used MR-RAPS<sup><xref ref-type="bibr" rid="c42">42</xref></sup> to accommodate many weak IVs with a higher <italic>P</italic>-value threshold. Sixty IVs were used with <italic>P</italic> &#x003C; 10<sup>&#x2212;4</sup> significance threshold and SNPs were clumped if R<sup>2</sup> &#x003E; 0.001 or located within 10 Mb from each other. The <italic>TERT</italic> locus was excluded from both Steiger filtering and Cochran&#x2019;s Q test, and one non-inferable palindromic SNP was excluded (Supplementary Table 6). The remaining fifty-eight SNPs were used as IVs and supported an inverse causal association of CHIP on LTL (&#x03B2; &#x003D; -0.017, <italic>P</italic> &#x003D; 0.04). Leave-one-out analysis showed the overlapping locus with one-sample MR analysis (<italic>KPNA4/TRIM59</italic>, rs4679885) is not a significant factor accounting for the causal inference (Supplementary Fig. 10).</p>
</sec>
<sec id="s2e">
<title>Mendelian randomization studies indicate that longer LTL cause CHIP acquisition</title>
<p>We performed one-sample MR using TOPMed individual-level data from LTL toward CHIP. IVs were discovered from GWAS of LTL conducted in an independent cohort<sup><xref ref-type="bibr" rid="c10">10</xref></sup> and pruned as 10 Mb apart and in linkage disequilibrium. Two-stage least square regression showed the causal association of LTL on all CHIP (Estimate &#x003D; 0.92, 95% CI 0.61:1.23; <italic>P</italic> &#x003D; 6.7&#x00D7;10<sup>&#x2212;9</sup>) (<xref rid="fig3" ref-type="fig">Fig. 3</xref>). Though Sargan test indicated endogeneity of used IVs (<italic>P</italic> &#x003C; 2.2&#x00D7;10<sup>&#x2212;16</sup>), we do not have an appropriate strategy to find pleiotropy in one-sample MR. Hence, the analysis was re-examined after exclusion of outliers detected by MR-PRESSO in the following replication analysis. Outlier exclusion still demonstrated significant causal association (Estimate &#x003D; 0.48; 95% CI 0.13:0.83; <italic>P</italic> &#x003D; 0.0062) without statistically significant evidence of pleiotropy (Sargan test; <italic>P</italic> &#x003D; 0.83).</p>
<p>A replication analysis was performed by two-sample MR studies. Previous LTL summary statistics<sup><xref ref-type="bibr" rid="c10">10</xref></sup> were used as the exposure and the white British subset of the UK Biobank was used as the CHIP outcome cohort (N &#x003D; 42,201), which are both independent from TOPMed used in one-sample MR. The positive potential causal effect of LTL on CHIP was shown in the conventional two-sample MR approach (Inverse Variance Weighted (IVW) method; Estimate &#x003D; 1.06; 95% CI 0.39:1.74; <italic>P</italic> &#x003D; 1.89&#x00D7;10<sup>&#x2212;3</sup>) (Supplementary Fig. 11). The global test by MR-PRESSO<sup><xref ref-type="bibr" rid="c43">43</xref></sup> suggested significant horizontal pleiotropy before outlier exclusion (<italic>P</italic> &#x003C; 1.0&#x00D7;10<sup>&#x2212;4</sup>) and detected the <italic>TERT</italic> and <italic>ATM</italic> loci as outliers (Supplementary Table 7). While the leave-one-out analysis showed the <italic>TERT</italic> locus variant had the most significant effect among IVs, the analysis remained robust (Supplementary Fig. 12). Outlier exclusion supported a significant causal association of LTL on CHIP by MR-PRESSO in two-sample MR (Estimate &#x003D; 0.79; 95% CI 0.24:1.34; <italic>P</italic> &#x003D; 0.014) (Supplementary Fig. 11) without significant statistical evidence of horizontal pleiotropy (Global Test: <italic>P</italic> &#x003D; 0.15). Re-evaluation of all the models after outlier exclusion showed stable estimates across methods indicating robust causal inference (Supplementary Fig. 13).</p>
<p>We next evaluated the relationship of LTLs with the occurrence of acquired genome-wide singleton single nucleotide substitution. Using WGS from a subset of the TOPMed study population (N &#x003D; 28,392), we tabulated per-individual genome-wide somatic mutations. Outlier-excluded 14 IVs discovered in the previous section were used for MR study. MR analyses supported a causal relationship between longer LTL and increased somatic mutations in one-sample MR study (Supplementary Fig. 14). Next, we assessed the effect of LTL for COSMIC signature version 2 (<ext-link ext-link-type="uri" xlink:href="https://cancer.sanger">https://cancer.sanger</ext-link>. ac.uk/cosmic/signatures_v2). Failure of DNA double-strand break repair by homologous recombination (Signature 3) and other signatures with unknown etiologies (Signatures 17, 28, and 30) associate with longer LTL in MR study (Supplementary Fig. 15). These observations suggested that longer LTL promotes CHIP acquisition by accelerating mutagenesis. The <italic>TERT</italic> locus variant associated prominently with mutational occurrence in line with the pleiotropic effect detected in MR studies (Supplementary Fig. 16).</p>
</sec>
<sec id="s2f">
<title>Causal Mediation analysis of LTL for CHIP associated CAD risks</title>
<p>We assessed the mediation effect of LTL on CHIP-associated CAD risk in UK Biobank. The proportion of mediation effect of LTL in the total effect of CHIP to CAD was estimated as 1.47 % (95% CI 0.18:5.3 %; <italic>P</italic> &#x003D; 0.02) using &#x201C;<italic>mediation</italic>&#x201D; package<sup><xref ref-type="bibr" rid="c44">44</xref></sup> in R (R Foundation for Statistical Computing, Vienna, Austria) (<xref rid="tbl1" ref-type="table">Table 1</xref>). Both mediator and outcome models were adjusted for age, sex, ever smoking, previous type 2 diabetes mellitus, previous hypercholesterolemia, previous hypertension, and the first 11 genetic PCs. We performed a replication analysis using the Women&#x2019;s Health Initiative (WHI) cohort subset of the TOPMed cohort (N &#x003D; 3,734), since sufficient covariates information to adjust models precisely were available. CAD was defined as the composite of myocardial infarction and coronary revascularization. The proportion of causal mediation effect of LTL in the total effect of CHIP to CAD was estimated as 5.2 % (95% CI 0. 10:33 %; <italic>P</italic> &#x003D; 0.02) in WHI.</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1:</label>
<caption><title>Causal mediation analysis showed mediation effect of LTL for CHIP associated CAD risk.</title>
<p>The mediation effect of LTL for CHIP associated CAD risk were estimated by &#x201C;mediation&#x201D; package in R. Mediation effect of 0 indicates that LTL does not mediate the CHIP associated CAD risks, and mediation effect of 1 indicate that LTL mediates all of the CHIP related CAD risks. The <italic>P</italic>-value reflects whether the proportion of the mediation effect on the CHIP related CAD risks is 0 vs. not 0. Both mediator and outcome models are adjusted by age, sex, ever smoking, prevalent type 2 diabetes, prevalent hypercholesterolemia, prevalent hypertension, and the first 11 genetic principal components in UK Biobank, and age at blood draw, ever smoking, race, dyslipidemia, hypertension, body mass index, WHI inverse probability weight (to account for the non-random selection of women for whole genome sequencing in WHI), history of hormone therapy, history of hysterectomy, and first 11 genetic principal components in WHI. CAD: coronary artery disease, CHIP: clonal hematopoiesis of intermediate potential, LTL: leukocyte telomere length, WHI: Women&#x2019;s Health Initiative.</p></caption>
<graphic xlink:href="21252199v1_tbl1.tif"/>
</table-wrap>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>We used observational and Mendelian randomization studies to examine how processes regulating LTL and CHIP acquisition interrelate, and how they influence CAD risk. Consistent with prior observational epidemiologic analyses, CHIP and LTL were inversely correlated. Bidirectional Mendelian randomization supported the hypotheses that longer LTL promotes CHIP acquisition whereas CHIP in turn shortens LTL potentially in affected cells. While both CHIP and shorter LTL have been independently associated with CAD, causal mediation analysis indicated that a modest fraction of CHIP-associated CAD risk may be mediated by resultant LTL shortening.</p>
<p>Our findings have several implications for the understanding of CHIP, LTL, and CAD. First, we observe a bidirectional causal relationship between LTL and CHIP, advancing our understanding of the malignancy-telomere length association. As described earlier, prior studies have shown complex relationships between LTL and cancer risk.<sup><xref ref-type="bibr" rid="c21">21</xref></sup> Several models were proposed, including a heterogeneous multi-hit theory<sup><xref ref-type="bibr" rid="c45">45</xref></sup> and the biphasic effect of <italic>TERT</italic> promoter mutation throughout tumor development.<sup><xref ref-type="bibr" rid="c14">14</xref></sup> CHIP provides an opportunity to focus on an incipient step of malignant cell development. Our results suggest that longer LTL may promote CHIP acquisition through increasing mutagenesis. One potential model could be that longer telomeres support the longevity of the cells, thus augmenting opportunities to acquire somatic mutations over time, while telomeres begin accelerated shortening once the cell cycle accelerates due to driver mutation acquisition (<xref rid="fig4" ref-type="fig">Fig. 4</xref>). Consistent with this model, we observed that increased clone size, a readout of increased cellular cycles, is correlated with shorter LTL.<sup><xref ref-type="bibr" rid="c46">46</xref></sup> In the setting of shortened telomere Mendelian syndromes, shortened telomeres promote genomic instability and subsequent acquisition and retention of neoplastic driver mutations.<sup><xref ref-type="bibr" rid="c47">47</xref></sup> This may be consistent with the observation that CHIP-associated LTL shortening may hasten subsequent malignancy (Supplementary Fig. 17). Further assessment of longitudinal LTL followup among CHIP positive population would be desired.</p>
<fig id="fig4" position="float" fig-type="figure">
<label>Fig. 4:</label>
<caption><title>Proposed model of &#x201C;Telomere Paradox&#x201D; in CHIP.</title>
<p>People with longer mean leukocyte telomere length (LTL) have higher incidence of mutagenesis so that have higher chance to acquire CHIP associated mutations (middle). The cells that acquired CHIP have paradoxically shorter telomeres so that mean LTL decreases as the clone expands (bottom). CHIP: clonal hematopoiesis of intermediate potential, LTL: leukocyte telomere length, HSPC: hematopoietic stem cell.</p></caption>
<graphic xlink:href="21252199v1_fig4.tif"/>
</fig>
<p>Second, CHIP-associated CAD risk may be partly attributed to subsequent LTL shortening. Prior cell-based, murine, and human genetic analyses have prioritized the NLRP3 inflammasome pathway in CHIP-associated CAD risk.<sup><xref ref-type="bibr" rid="c24">24</xref>-<xref ref-type="bibr" rid="c27">27</xref>,<xref ref-type="bibr" rid="c29">29</xref>,<xref ref-type="bibr" rid="c48">48</xref>,<xref ref-type="bibr" rid="c49">49</xref></sup> In the present work, we orthogonally implicate LTL in both the genesis of CHIP, a new CAD risk factor, and its clinical consequences. Our study is underpowered for gene-specific analyses but notably did not observe an association between <italic>DNMT3A</italic> CHIP and LTL alteration. Consistent with this observation, prior work suggests that hematopoietic stem cell loss of <italic>Tet2</italic> leads to shortened telomeres, whereas loss of <italic>Dnmt3a</italic> leads to telomere preservation.<sup><xref ref-type="bibr" rid="c35">35</xref>,<xref ref-type="bibr" rid="c50">50</xref></sup> Such differences may also partly explain gene-specific differences in CAD risk.<sup><xref ref-type="bibr" rid="c25">25</xref>-<xref ref-type="bibr" rid="c27">27</xref></sup> While interrupting CHIP-mediated LTL shortening may be a viable strategy to mitigate CHIP-associated CAD risk, this general strategy may be limited to the overall modest estimated mediating effect. However, given heterogeneity observed, this strategy may be more efficiently applied to non-<italic>DNMT3A</italic> CHIP.</p>
<p>Key limitations must be considered in the interpretation of our study findings. First, limited CHIP GWAS availability prevented conventional two-sample MR approaches for CHIP on LTL. The ongoing effort of accumulating CHIP cases would address this issue. Second, the cross-sectional observational nature of our analyses limits inference regarding causal temporal relationships. We employ several sensitivity analyses for Mendelian randomization for robustness. Longitudinal analyses of LTL, CHIP, and incident diseases as well as experimental models are needed to confirm our hypotheses. Third, the causal mediation effect estimate of LTL for CHIP-associated CAD may be limited by conflicting bidirectional causal effect.</p>
<p>In conclusion, we showed a bidirectional relationship between LTL and CHIP, shedding light on the mechanisms by which telomere length contributes to age-related disorders. The causal mediation effect of LTL on CHIP-related CAD incidence suggests the plausibility of developing harmonized therapies for both blood cancer and cardiovascular diseases.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material>
<label>Supplementary Materials</label>
<media xlink:href="supplements/252199_file02.pdf" />
</supplementary-material>
<supplementary-material>
<label>Supplementary Table 4</label>
<media xlink:href="supplements/252199_file03.xlsx" />
</supplementary-material>
</sec>
</body>
<back>
<sec sec-type="data-availability">
<title>Data Availability</title>
<p>Data from TOPMed are available via dbGaP.
Data from UK Biobank will be made available through an application.</p>
</sec>
<ref-list>
<title>Reference</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Sfeir</surname>, <given-names>A.</given-names></string-name> &#x0026; <string-name><surname>de Lange</surname>, <given-names>T.</given-names></string-name> <article-title>Removal of Shelterin Reveals the Telomere End-Protection Problem</article-title>. <source>Science</source> <volume>336</volume>, <fpage>593</fpage>&#x2013;<lpage>597</lpage> (<year>2012</year>).</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Blackburn</surname>, <given-names>E. H.</given-names></string-name>, <string-name><surname>Epel</surname>, <given-names>E. S.</given-names></string-name> &#x0026; <string-name><surname>Lin</surname>, <given-names>J.</given-names></string-name> <article-title>Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection</article-title>. <source>Science</source> <volume>350</volume>, <fpage>1193</fpage>&#x2013;<lpage>1198</lpage> (<year>2015</year>).</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Allsopp</surname>, <given-names>R. C.</given-names></string-name> <etal>et al.</etal> <article-title>Telomere length predicts replicative capacity of human fibroblasts</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A</source>. <volume>89</volume>, <fpage>10114</fpage>&#x2013;<lpage>10118</lpage> (<year>1992</year>).</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Brouilette</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Singh</surname>, <given-names>R. K.</given-names></string-name>, <string-name><surname>Thompson</surname>, <given-names>J. R.</given-names></string-name>, <string-name><surname>Goodall</surname>, <given-names>A. H.</given-names></string-name> &#x0026; <string-name><surname>Samani</surname>, <given-names>N. J.</given-names></string-name> <article-title>White Cell Telomere Length and Risk of Premature Myocardial Infarction</article-title>. <source>Arterioscler. Thromb. Vasc. Biol</source>. <volume>23</volume>, <fpage>842</fpage>&#x2013;<lpage>846</lpage> (<year>2003</year>).</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Vasa-Nicotera</surname>, <given-names>M.</given-names></string-name> <etal>et al.</etal> <article-title>Mapping of a Major Locus that Determines Telomere Length in Humans</article-title>. <source>The American Journal of Human Genetics</source> <volume>76</volume>, <fpage>147</fpage>&#x2013;<lpage>151</lpage> (<year>2005</year>).</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Zhan</surname>, <given-names>Y.</given-names></string-name> &#x0026; <string-name><surname>H&#x00E4;gg</surname>, <given-names>S.</given-names></string-name> <article-title>Telomere length and cardiovascular disease risk</article-title>. <source>Curr. Opin. Cardiol</source>. <volume>34</volume>, <fpage>270</fpage>&#x2013;<lpage>274</lpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Childs</surname>, <given-names>B. G.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>H.</given-names></string-name> &#x0026; <string-name><surname>van Deursen</surname>, <given-names>J. M.</given-names></string-name> <article-title>Senescent cells: a therapeutic target for cardiovascular disease</article-title>. <source>J. Clin. Invest</source>. <volume>128</volume>, <fpage>1217</fpage>&#x2013;<lpage>1228</lpage> (<year>2018</year>).</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Ojha</surname>, <given-names>J.</given-names></string-name> <etal>et al.</etal> <article-title>Genetic Variation Associated with Longer Telomere Length Increases Risk of Chronic Lymphocytic Leukemia</article-title>. <source>Cancer Epidemiol. Biomarkers. Prev</source>. <volume>25</volume>, <fpage>1043</fpage>&#x2013;<lpage>1049</lpage> (<year>2016</year>).</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Haycock</surname>, <given-names>P. C.</given-names></string-name> <etal>et al.</etal> <article-title>Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study</article-title>. <source>JAMA Oncol</source>. <volume>3</volume>, <fpage>636</fpage>&#x2013;<lpage>651</lpage> (<year>2017</year>).</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Li</surname>, <given-names>C.</given-names></string-name> <etal>et al.</etal> <article-title>Genome-wide Association Analysis in Humans Links Nucleotide Metabolism to Leukocyte Telomere Length</article-title>. <source>The American Journal of Human Genetics</source> <volume>106</volume>, <fpage>389</fpage>&#x2013;<lpage>404</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Murnane</surname>, <given-names>J. P.</given-names></string-name> <article-title>Telomeres and chromosome instability</article-title>. <source>DNA Repair</source> <volume>5</volume>, <fpage>1082</fpage>&#x2013;<lpage>1092</lpage> (<year>2006</year>).</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Sommerfeld</surname>, <given-names>H. J.</given-names></string-name> <etal>et al.</etal> <article-title>Telomerase activity: a prevalent marker of malignant human prostate tissue</article-title>. <source>Cancer Research</source> <volume>56</volume>, <fpage>218</fpage>&#x2013;<lpage>222</lpage> (<year>1996</year>).</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Meeker</surname>, <given-names>A. K.</given-names></string-name> <etal>et al.</etal> <article-title>Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis</article-title>. <source>Cancer Research</source> <volume>62</volume>, <fpage>6405</fpage>&#x2013;<lpage>6409</lpage> (<year>2002</year>).</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Chiba</surname>, <given-names>K.</given-names></string-name> <etal>et al.</etal> <article-title>Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism</article-title>. <source>Science</source> <volume>357</volume>, <fpage>1416</fpage>&#x2013;<lpage>1420</lpage> (<year>2017</year>).</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Barthel</surname>, <given-names>F. P.</given-names></string-name> <etal>et al.</etal> <article-title>Systematic analysis of telomere length and somatic alterations in 31 cancer types</article-title>. <source>Nat. Genet</source>. <volume>49</volume>, <fpage>349</fpage>&#x2013;<lpage>357</lpage> (<year>2017</year>).</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Mary Armanios</surname>, <given-names>E.H.B.</given-names></string-name> <article-title>The telomere syndromes</article-title>. <source>Nat. Rev. Genet</source>. <volume>13</volume>, <fpage>693</fpage>&#x2013;<lpage>704</lpage> (<year>2012</year>).</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Mangaonkar</surname>, <given-names>A. A.</given-names></string-name> &#x0026; <string-name><surname>Patnaik</surname>, <given-names>M. M.</given-names></string-name> <article-title>Short Telomere Syndromes in Clinical Practice: Bridging Bench and Bedside</article-title>. <source>Mayo Clinic Proceedings</source> <volume>93</volume>, <fpage>904</fpage>&#x2013;<lpage>916</lpage> (<year>2018</year>).</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Nan</surname>, <given-names>H.</given-names></string-name> <etal>et al.</etal> <article-title>Shorter Telomeres Associate with a Reduced Risk of Melanoma Development</article-title>. <source>Cancer Research</source> <volume>71</volume>, <fpage>6758</fpage>&#x2013;<lpage>6763</lpage> (<year>2011</year>).</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Lynch</surname>, <given-names>S. M.</given-names></string-name> <etal>et al.</etal> <article-title>A prospective analysis of telomere length and pancreatic cancer in the alpha-tocopherol beta-carotene cancer (ATBC) prevention study</article-title>. <source>Int. J. Cancer</source> <volume>133</volume>, <fpage>2672</fpage>&#x2013;<lpage>2680</lpage> (<year>2013</year>).</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Julin</surname>, <given-names>B.</given-names></string-name> <etal>et al.</etal> <article-title>Circulating leukocyte telomere length and risk of overall and aggressive prostate cancer</article-title>. <source>Br. J. Cancer</source> <volume>112</volume>, <fpage>769</fpage>&#x2013;<lpage>776</lpage> (<year>2015</year>).</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>McNally</surname>, <given-names>E. J.</given-names></string-name>, <string-name><surname>Luncsford</surname>, <given-names>P. J.</given-names></string-name> &#x0026; <string-name><surname>Armanios</surname>, <given-names>M.</given-names></string-name> <article-title>Long telomeres and cancer risk: the price of cellular immortality</article-title>. <source>J. Clin. Invest</source>. <volume>129</volume>, <fpage>3474</fpage>&#x2013;<lpage>3481</lpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Xie</surname>, <given-names>M.</given-names></string-name> <etal>et al.</etal> <article-title>Age-related mutations associated with clonal hematopoietic expansion and malignancies</article-title>. <source>Nat. Med</source>. <volume>20</volume>, <fpage>1472</fpage>&#x2013;<lpage>1478</lpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Genovese</surname>, <given-names>G.</given-names></string-name> <etal>et al.</etal> <article-title>Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence</article-title>. <source>N. Engl. J. Med</source>. <volume>371</volume>, <fpage>2477</fpage>&#x2013;<lpage>2487</lpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><string-name><surname>Jaiswal</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal> <article-title>Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes</article-title>. <source>N. Engl. J. Med</source>. <volume>371</volume>, <fpage>2488</fpage>&#x2013;<lpage>2498</lpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Jaiswal</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal> <article-title>Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease</article-title>. <source>N. Engl. J. Med</source>. <volume>377</volume>, <fpage>111</fpage>&#x2013;<lpage>121</lpage> (<year>2017</year>).</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>Fuster</surname>, <given-names>J. J.</given-names></string-name> <etal>et al.</etal> <article-title>Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice</article-title>. <source>Science</source> <volume>355</volume>, <fpage>842</fpage>&#x2013;<lpage>847</lpage> (<year>2017</year>).</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><string-name><surname>Bick</surname>, <given-names>A. G.</given-names></string-name> <etal>et al.</etal> <article-title>Genetic Interleukin 6 Signaling Deficiency Attenuates Cardiovascular Risk in Clonal Hematopoiesis</article-title>. <source>Circulation</source> <volume>141</volume>, <fpage>124</fpage>&#x2013;<lpage>131</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>Zink</surname>, <given-names>F.</given-names></string-name> <etal>et al.</etal> <article-title>Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly</article-title>. <source>Blood</source> <volume>130</volume>, <fpage>742</fpage>&#x2013;<lpage>752</lpage> (<year>2017</year>).</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><string-name><surname>Bick</surname>, <given-names>A. G.</given-names></string-name> <etal>et al.</etal> <article-title>Inherited causes of clonal haematopoiesis in 97,691 whole genomes</article-title>. <source>Nature</source> <volume>586</volume>, <fpage>1</fpage>&#x2013;<lpage>24</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="website"><string-name><surname>Taub</surname>, <given-names>M. A.</given-names></string-name> <etal>et al.</etal> <article-title>Novel genetic determinants of telomere length from a multiethnic analysis of 75,000 whole genome sequences in TOPMed</article-title>. <source>Preprint at bioRxiv</source> <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1101/749010">https://doi.org/10.1101/749010</ext-link> (<year>2019</year>).</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><string-name><surname>Ding</surname>, <given-names>Z.</given-names></string-name> <etal>et al.</etal> <article-title>Estimating telomere length from whole genome sequence data</article-title>. <source>Nucleic Acids Research</source> <volume>42</volume>, <fpage>e75</fpage>&#x2013;<lpage>e75</lpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Taliun</surname>, <given-names>D.</given-names></string-name> <etal>et al.</etal> <article-title>Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program</article-title>. <source>Nature</source> <volume>590</volume>, <fpage>290</fpage>&#x2013;<lpage>299</lpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><string-name><surname>Van Hout</surname>, <given-names>C. V.</given-names></string-name> <etal>et al.</etal> <article-title>Exome sequencing and characterization of 49,960 individuals in the UK Biobank</article-title>. <source>Nature</source> <volume>586</volume>, <fpage>749</fpage>&#x2013;<lpage>756</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><string-name><surname>Gonzalo</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal> <article-title>DNA methyltransferases control telomere length and telomere recombination in mammalian cells</article-title>. <source>Nature Cell Biology</source> <volume>8</volume>, <fpage>416</fpage>&#x2013;<lpage>424</lpage> (<year>2006</year>).</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><string-name><surname>Yang</surname>, <given-names>J.</given-names></string-name> <etal>et al.</etal> <article-title>Tet Enzymes Regulate Telomere Maintenance and Chromosomal Stability of Mouse ESCs</article-title>. <source>Cell Rep</source>. <volume>15</volume>, <fpage>1809</fpage>&#x2013;<lpage>1821</lpage> (<year>2016</year>).</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><string-name><surname>Bernard</surname>, <given-names>L.</given-names></string-name> <etal>et al.</etal> <article-title>Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms</article-title>. <source>Leukemia</source> <volume>23</volume>, <fpage>287</fpage>&#x2013;<lpage>291</lpage> (<year>2009</year>).</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><string-name><surname>Tutton</surname>, <given-names>S.</given-names></string-name> &#x0026; <string-name><surname>Lieberman</surname>, <given-names>P. M.</given-names></string-name> <article-title>A role for p53 in telomere protection</article-title>. <source>Molecular &#x0026; Cellular Oncology</source> <volume>4</volume>, <fpage>e1143078</fpage> (<year>2017</year>).</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><string-name><surname>Haycock</surname>, <given-names>P. C.</given-names></string-name> <etal>et al.</etal> <article-title>Leukocyte telomere length and risk of cardiovascular disease: systematic review and meta-analysis</article-title>. <source>BMJ</source> <volume>349</volume>, <fpage>g4227</fpage>&#x2013;<lpage>g4227</lpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><string-name><surname>D&#x2019;Mello</surname>, <given-names>M. J. J.</given-names></string-name> <etal>et al.</etal> <article-title>Association Between Shortened Leukocyte Telomere Length and Cardiometabolic Outcomes</article-title>. <source>Circ. Cardiovasc. Genet</source>. <volume>8</volume>, <fpage>82</fpage>&#x2013;<lpage>90</lpage> (<year>2015</year>).</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><string-name><surname>Hunt</surname>, <given-names>S. C.</given-names></string-name>, <string-name><surname>Kark</surname>, <given-names>J. D.</given-names></string-name> &#x0026; <string-name><surname>Aviv</surname>, <given-names>A.</given-names></string-name> <article-title>Association Between Shortened Leukocyte Telomere Length and Cardio-Metabolic Outcomes</article-title>. <source>Circ. Cardiovasc. Genet</source>. <volume>8</volume>, <fpage>4</fpage>&#x2013;<lpage>7</lpage> (<year>2015</year>).</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><string-name><surname>Codd</surname>, <given-names>V.</given-names></string-name> <etal>et al.</etal> <article-title>Identification of seven loci affecting mean telomere length and their association with disease</article-title>. <source>Nat. Genet</source>. <volume>45</volume>, <fpage>422</fpage>&#x2013;<lpage>7</lpage>&#x2013; 427e1&#x2013;2 (<year>2013</year>).</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><string-name><surname>Zhao</surname>, <given-names>Q.</given-names></string-name> <etal>et al.</etal> <article-title>Statistical inference in two-sample summary-data mendelian randomization using robust adjusted profile score</article-title>. <source>Ann. Statist</source>. <volume>48</volume>, <fpage>1742</fpage>&#x2013;<lpage>1769</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><string-name><surname>Verbanck</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>C. Y.</given-names></string-name>, <string-name><surname>Neale</surname>, <given-names>B.</given-names></string-name> &#x0026; <string-name><surname>Do</surname>, <given-names>R.</given-names></string-name> <article-title>Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases</article-title>. <source>Nat. Genet</source>. <volume>50</volume>, <fpage>693</fpage>&#x2013;<lpage>698</lpage> (<year>2018</year>).</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><string-name><surname>Tingley</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Yamamoto</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Hirose</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Keele</surname>, <given-names>L.</given-names></string-name> &#x0026; <string-name><surname>Imai</surname>, <given-names>K.</given-names></string-name> <article-title>mediation: R Package for Causal Mediation Analysis</article-title>. <source>Journal of Statistical Software</source> <volume>59</volume>, <fpage>1</fpage>&#x2013;<lpage>38</lpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><string-name><surname>Aviv</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Anderson</surname>, <given-names>J. J.</given-names></string-name> &#x0026; <string-name><surname>Shay</surname>, <given-names>J. W.</given-names></string-name> <article-title>Mutations, Cancer and the Telomere Length Paradox</article-title>. <source>Trends in Cancer</source> <volume>3</volume>, <fpage>253</fpage>&#x2013;<lpage>258</lpage> (<year>2017</year>).</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><string-name><surname>Watson</surname>, <given-names>C. J.</given-names></string-name> <etal>et al.</etal> <article-title>The evolutionary dynamics and fitness landscape of clonal hematopoiesis</article-title>. <source>Science</source> <volume>367</volume>, <fpage>1449</fpage>&#x2013;<lpage>1454</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><string-name><surname>Blasco</surname>, <given-names>M. A.</given-names></string-name> <etal>et al.</etal> <article-title>Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA</article-title>. <source>Cell</source> <volume>91</volume>, <fpage>25</fpage>&#x2013;<lpage>34</lpage> (<year>1997</year>).</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><string-name><surname>Sano</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal> <article-title>CRISPR-Mediated Gene Editing to Assess the Roles of Tet2 and Dnmt3a in Clonal Hematopoiesis and Cardiovascular Disease</article-title>. <source>Circ. Res</source>. <volume>123</volume>, <fpage>335</fpage>&#x2013;<lpage>341</lpage> (<year>2018</year>).</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="other"><string-name><surname>Abplanalp</surname>, <given-names>W. T.</given-names></string-name> <etal>et al.</etal> <article-title>Association of Clonal Hematopoiesis of Indeterminate Potential With Inflammatory Gene Expression in Patients With Severe Degenerative Aortic Valve Stenosis or Chronic Postischemic Heart Failure</article-title>. <source>JAMA Cardiol</source>. (<year>2020</year>).</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><string-name><surname>Jeong</surname>, <given-names>M.</given-names></string-name> <etal>et al.</etal> <article-title>Loss of Dnmt3a Immortalizes Hematopoietic Stem Cells In Vivo</article-title>. <source>Cell Rep</source>. <volume>23</volume>, <fpage>1</fpage>&#x2013;<lpage>10</lpage> (<year>2018</year>).</mixed-citation></ref>
</ref-list>
</back>
</article>